Erythrocytic-stage Plasmodium species

Erythrocytic-stage Plasmodium species refers to the asexual phase of the malaria parasite's life cycle that occurs within human red blood cells [CDC, 2023]. This stage is responsible for all the clinical symptoms and pathology associated with malaria, including fever, anemia, and organ failure [WHO, 2022]. During this phase, the parasite undergoes cycles of invasion, growth, and replication, consuming host hemoglobin and releasing merozoites that infect new erythrocytes [Nature Reviews Microbiology, 2018]. Most current antimalarial drugs target this stage to reduce parasite burden and alleviate symptoms [PubMed, PMC6121587]. However, the high rate of mutation in Plasmodium species has led to widespread drug resistance, necessitating the continuous development of new therapeutic strategies targeting specific parasite enzymes and pathways within this stage [The Lancet Infectious Diseases, 2021].

Other names

Blood-stage malaria parasitesIntraerythrocytic PlasmodiumAsexual blood-stage PlasmodiumErythrocytic Plasmodium falciparum

Antimalarials targeting this stage act through various mechanisms, including the inhibition of heme biocrystallization into non-toxic hemozoin (e.g., quinolines), the generation of free radicals that damage parasite membranes (e.g., artemisinins), and the inhibition of essential metabolic pathways like folate synthesis (e.g., pyrimethamine) or mitochondrial electron transport (e.g., atovaquone) [Nature Reviews Microbiology, 2018, 16(7):428-440].